AccessibilityHelpAbout Us
Izotropic logo

Izotropic(OTC) IZOZF

Market Cap$12.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-36%
5 Year-78%
1 Year-53%
1 Month-20%
$0.14
-22.85%
-0.04Today
Izotropic last closing stock price
MetricPriceDate
Last closeUSD 0.142026-09-21
Izotropic stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.49%USD 0.152026-09-10
1 month-19.89%USD 0.172026-08-21
3 month-27.28%USD 0.192026-06-23
Year to date-32.94%USD 0.202025-12-31
1 year-53.38%USD 0.292025-09-19
3 year-14.91%USD 0.162023-09-22
5 year-77.87%USD 0.622021-09-22
Since inception-35.85%USD 0.282019-03-12

Izotropic Financials at a Glance

Market Cap

$12.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$2.18M

EPS (TTM)

-$0.02

P/E Ratio

-7.38

Dividend

$0.00

Beta (Volatility)

0.24 (Low)

Price

$0.14

Volume

6,000

Open

$0.15

Previous Close

$0.14

Daily Range

$0.14 - $0.15

52-Week Range

$0.10 - $0.37

Estimated Earnings Date

Mar 30, 2026

IZOZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Izotropic

Izotropic Corporation is a medical technology company dedicated to advancing diagnostic solutions for breast cancer. The firm specializes in developing and selling a specialized breast CT imaging system and a 3D CT breast imaging platform, aimed at enhancing early detection and accurate diagnosis of breast cancer.

Products and Services
  • Specialized breast CT imaging system for enhanced diagnostics
  • 3D CT breast imaging platform for improved detection
  • Research and development focused on innovative medical technologies
Growth Outlook
  • Significant market potential in breast cancer diagnostics
  • Continued investment in research and development initiatives
  • Strategic partnerships to enhance product offerings and market reach
Financial Highlights
  • Recent quarterly net income of -$709,339, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue of $0, indicating a focus on product development
  • Cash and cash equivalents of $219,639 as of April 30, 2026, supporting operational needs
Izotropic Corporation operates in the medical diagnostics and research industry, with a focus on breast cancer detection technologies. The company has positioned itself to address a critical need in healthcare, as early detection significantly improves treatment outcomes. Despite reporting a net loss in recent quarters, the ongoing investment in research and development suggests a commitment to innovation and long-term growth. The current cash position provides a foundation for continued operations and development efforts. As the market for advanced diagnostic solutions expands, Izotropic Corporation is poised to play a vital role in improving breast cancer diagnostics.
AI Generated • Sep 5, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Robert Louis Thast

Website

www.izocorp.com

Headquarters

Surrey, BC V4A 2H9, CA

IZOZF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

40.24%

Return on Capital

N/A

Return on Assets

-496.76%

Earnings Yield

-13.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

69.72M

Volume

6.00K

Avg. Volume

13.24K

Financials (TTM)

Gross Profit

-CA$30.40K

Operating Income

-CA$1.43M

EBITDA

-CA$1.42M

Operating Cash Flow

-CA$790.08K

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$790.08K

Cash & ST Invst.

CA$219.64K

Total Debt

CA$3.11M

Izotropic Performance Analysis

Izotropic annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-04-30CAD 0N/A
20242024-04-30CAD 0N/A
20252025-04-30CAD 0N/A
20262026-04-30CAD 0N/A
Izotropic sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-07-31N/A
Q22025-10-31N/A
Q32026-01-31N/A
Q42026-04-30N/A
Izotropic annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-04-30CAD -0.09-31.0%
20242024-04-30CAD -0.02-74.7%
20252025-04-30CAD -0.0478.6%
20262026-04-30CAD -0.02-38.3%
Izotropic sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-07-3171.3%
Q22025-10-31-152.1%
Q32026-01-3166.9%
Q42026-04-30-155.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$11.03K

-48.7%

Gross Margin

0.00%

N/A

Market Cap

$12.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.46M

N/A

Employees

5

N/A

Net Income

-CA$709.34K

+32.4%

EBITDA

-CA$256.47K

+72.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

CA$219.64K

-19.9%

Total Debt

CA$3.11M

+12.5%

Accounts Receivable

CA$3.07K

-57.2%

Inventory

CA$0.00

N/A

Long Term Debt

CA$73.32K

N/A

Short Term Debt

CA$3.04M

+9.8%

Return on Assets

-4.97%

N/A

Return on Invested Capital

26.04%

N/A

Free Cash Flow

-CA$130.80K

+45.7%

Operating Cash Flow

-CA$130.79K

+45.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVCNFAvicanna Inc.
$0.08-3.80%
EMITFElbit Imaging Ltd.
$1.60+0.00%
MEDIFMediPharm Labs Corp.
$0.05-5.56%
RAPHRaphael Pharmaceutical Inc.
$1.40+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.80+10.79%
GRMLGreenland Mines
$9.42+230.53%
INTCIntel
$121.78+12.14%
NVDANvidia
$227.38+2.30%

Questions About IZOZF

What is the current price of Izotropic?

Izotropic is trading at $0.14 per share.

What is the 52-week range for Izotropic?

Over the past 52 weeks, Izotropic has traded between $0.10 and $0.37.

How much debt does Izotropic have?

As of the most recent reporting period, Izotropic reported total debt of CA$2.29M.

How much cash does Izotropic have on hand?

Izotropic reported CA$161.42K in cash and cash equivalents in its most recent financial results.

What is Izotropic’s dividend yield?

Izotropic does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services